Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Paul Matteis has maintained a Buy rating on Dyne Therapeutics (DYN) with a price target of $36.00. Matteis, a 5-star analyst, has an average return of 19.6% and a success rate of 48.82%. Additionally, Piper Sandler also reiterated a Buy rating on Dyne Therapeutics with a higher price target of $48.00 in a report released on October 27.
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Dyne Therapeutics, with a price target of $36.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Matteis is a 5-star analyst with an average return of 19.6% and a 48.82% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Ionis Pharmaceuticals, and PepGen Inc..
In a report released on October 27, Piper Sandler also reiterated a Buy rating on the stock with a $48.00 price target.
